Advertisement

A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer

  • H. Olsson
  • Å. Borg
  • S. -B. Ewers
  • M. Fernö
  • T. Möller
  • J. Ranstam
Articles
  • 187 Downloads

Abstract

In a population-based group of women, consecutively diagnosed, with premenopausal breast cancer there was a significant correlation between tumour size and plasma prolactin (r=0.30;P<0.004). The concentration of estrogen receptor was negatively correlated to tumour size (r=−0.17;P<0.09). There were no substantial correlations between tumour size and progesterone receptor, plasma progesterone or estradiol. Adjustments for menstrual cycle day and age did not alter the above findings.

The ratio of plasma prolactin and estrogen receptor was significantly greater (P<0.037) for the group of the patients that had started using oral contraceptives before the age of 20 as compared with the other patients. Consequently, the tumour size was significantly greater in the group of early users (P<0.003).

The findings indicate that breast tumours developing in previous early users of oral contraceptives have a low estrogen receptor concentration, while these patients have plasma prolactin. The tumour size is greater in early users indicating a poorer prognosis than other women with breast cancer. As early use of oral contraceptives increases, breast cancer risk and a high ratio of plasma prolactin and estrogen receptor concentration of the primary tumour characterize early oral contraceptive users the ratio may be a valuable marker for the breast cancer risk.

Key words

Marker Premenopausal breast cancer Oral contraceptive use Estrogen receptor Progesterone receptor Plasma prolactin 

Abbreviations

ER

estrogen receptor concentration

PGR

Progesterone receptor concentration

OC-use

oral contraceptive use

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Henderson B E, Ross R K, Judd H L, Krailo M D, Pike M C: Do regular cycles increase breast cancer risk?Cancer 56, 1206 (1985).PubMedCrossRefGoogle Scholar
  2. 2.
    Paffenbarger R S, Fasal E, Simmons M E, Kampert J B: Cancer risk as related to use of oral contraceptives during fertile years.Cancer 39, 1887 (1977).PubMedCrossRefGoogle Scholar
  3. 3.
    Olsson H, Landin Olsson M, Möller T, Ranstam J, Holm P: Oral contraceptive use and breast cancer in young women in Sweden.Lancet 30, 749 (1985).Google Scholar
  4. 4.
    Olsson H, Ewers S-B, Landin Olsson M, Ranstam J: Relation between tumour size and plasma prolactin levels in premenopausal patients with breast carcinoma.Acta Radiol Oncol 24, 57 (1985).PubMedCrossRefGoogle Scholar
  5. 5.
    Mishell D R, Kletzky O A, Brenner P F, Roy S, Nicoloff J: The effect of contraceptive steroids on hypothalamic-pituitary function.Am J Obstet Gynecol 128, 60 (1977).PubMedGoogle Scholar
  6. 6.
    Thorell J I, Larsson S M:Radioimmunoassay and Related Techniques. St Louis, C. V. Mosby (1978).Google Scholar
  7. 7.
    Norgren A, Borg Å, Fernö M, Johanssson U, Lindahl B, Tsiobanelis K: Improved method for assay of estradiol and progesterone receptors with special reference to breast cancer.Anticancer Res,2, 315 (1982).PubMedGoogle Scholar
  8. 8.
    Pike M C, Henderson B E, Krailo M D, Duke A: Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use.Lancet 22, 926 (1983).CrossRefGoogle Scholar
  9. 9.
    McPherson K, Neil A, Vessey M P, Doll R: Oral contraceptives and breast cancer.Lancet 17, 1414 (1983).CrossRefGoogle Scholar
  10. 10.
    Olsson H, Möller T R, Ranstam J: P-pilleranvändning och bröstcancer. (In Swedish).Läkartidningen 82, 39, 3277 (1985).Google Scholar
  11. 11.
    Olsson H, Ranstam J, Möller T R: Breast cancer and oral contraceptives.Lancet 18, 1181 (1985).Google Scholar
  12. 12.
    Haagensen C D:Diseases of the Breast, 2nd edn, pp. 384–390. Philadelphia, W. B. Saunders (1971).Google Scholar
  13. 13.
    Bern H A, Talamantes F J: Neonatal mouse models and their relation to disease in the human female, in Herbst A L, Bern H A (eds).Developmental Effects of Diethylstilbestrol in Pregnancy, pp. 129–147. New York, Thieme-Stratton (1981).Google Scholar
  14. 14.
    McGuire W L: An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer, in Iacobelli Set al. (eds.):Hormones and Cancer, pp. 337–343. New York, Raven Press (1980).Google Scholar
  15. 15.
    Rose R M, Sachar E: Psychoendocrinology, in Williams R H (ed):Textbook of Endocrinology, 6th edn, p. 657. Philadelphia, W. B. Saunders (1981).Google Scholar

Copyright information

© Humana Press Inc. 1986

Authors and Affiliations

  • H. Olsson
    • 1
  • Å. Borg
    • 1
  • S. -B. Ewers
    • 1
  • M. Fernö
    • 1
  • T. Möller
    • 2
  • J. Ranstam
    • 2
  1. 1.Department of OncologyUniversity HospitalLund
  2. 2.Southern Swedish Regional Tumour RegistryLundSweden

Personalised recommendations